Outpatient-Based Bone Marrow Transplantation for Hematologic Malignancies: Cost Saving or Cost Shifting?
- 1 September 1999
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 17 (9) , 2811
- https://doi.org/10.1200/jco.1999.17.9.2811
Abstract
PURPOSE: To determine whether a shift in care from an inpatient-based to an outpatient-based bone marrow transplantation (BMT) program decreased charges to payers without increasing clinical complications or out-of-pocket costs to patients. PATIENTS AND METHODS: This nonrandomized prospective cohort study compared clinical and economic outcomes for 132 consecutive BMT patients with hematologic malignancies who received either inpatient- or outpatient-based BMT care. RESULTS: Seventeen of 132 BMT patients underwent outpatient-based BMT. Compared with the inpatient-based group, the outpatient-based group had a markedly lower mean number of inpatient hospital days (22 v 47; P < .001) and decreased mean inpatient facility charges ($61,059 less per patient; P < .0001) but had higher mean outpatient facility charges ($49,732 higher; P < .0001). Total professional fees were similar for the groups. The mean total charge to payers was only 7% less ($12,652; P = .21) for outpatient-based BMT than for inpatient-based BMT, but total charge was 34% less for outpatient compared with inpatient BMT ($54,240; P = 0.056) in a subset of patients who had a standard rather than high risk of treatment failure. There was no significant difference between groups in out-of-pocket costs for transportation, lodging, meals, home nursing, household assistance, child care, medication expenses, or unreimbursed medical bills. There also was no significant difference between groups in reported income lost, involuntary unemployment, or months of disability. The two groups had similar rates of major complications, including death, significant acute graft-versus-host disease, and veno-occlusive disease of the liver. CONCLUSION: Increased use of outpatient-based BMT should produce substantial cost savings for payers without adverse effects on patients for those patients who do not have a high risk of treatment failure.Keywords
This publication has 11 references indexed in Scilit:
- Cost analysis of the introduction of PBPC for autologous transplantation: effect of switching from bone marrow (BM) to peripheral blood progenitor cells (PBPC)Bone Marrow Transplantation, 1997
- Feasibility and cost-effectiveness of outpatient autotransplants in multiple myelomaBone Marrow Transplantation, 1997
- The True Cost of Bone Marrow TransplantationThe Lancet Healthy Longevity, 1997
- Peripheral Blood Stem Cell and Bone Marrow Transplantation for Solid Tumors and Lymphomas: Hematologic Recovery and Costs: A Randomized, Controlled TrialAnnals of Internal Medicine, 1997
- Cost-effectiveness of autologous bone marrow transplantation in patients with relapsed non-Hodgkin’s lymphomaBone Marrow Transplantation, 1997
- Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma.Journal of Clinical Oncology, 1997
- The use of bone marrow and peripheral blood stem cell transplantation in the treatment of cancerCA: A Cancer Journal for Clinicians, 1996
- A Review of the Costs, Cost‐Effectiveness and Third‐Party Charges of Bone Marrow TransplantationThe International Journal of Cell Cloning, 1996
- Efficacy and Cost-effectiveness of Autologous Bone Marrow Transplantation in Metastatic Breast CancerJAMA, 1992
- Increasing Utilization of Allogeneic Bone Marrow TransplantationAnnals of Internal Medicine, 1992